DOI: 10.26717/BJSTR.2017.01.000159
*Corresponding author:
Nahla A M Hamed, Faculty of Medicine, Alexandria University, EgyptReceived: June 26, 2017 Published: June 29, 2017
To view the Full Article Peer-reviewed Article PDF
The PD-1/PD-L1 pathway plays an important role in mediating immune tolerance in physiological stateand is an important mechanism by which malignancies can evade the host immune response. PD-1 inhibitors may be particularly attractive for hematologic malignancies because the activation of adoptive immunity has been proven effective in the form of allogeneic stem cell transplantation. Clinical trials of anti-PD-1 monoclonal antibodies have demonstrated promising results in lymphoma patients with advanced disease.
Abbreviations: PD-1: Programmed Death-1; FL: Follicular Lymphoma; CHL: Classical Hodgkin Lymphoma; BL: Burkitt Lymphoma; DLBCL: Diffuse Large B-Cell Lymphoma; PI3K: Phosphatidylinositol-4,5-Bisphosphate 3-Kinase; PTEN: Phosphatase And Tensin Homologue; PCNSL: Primary Central Nervous System Lymphoma; PTL: Primary Testicular Lymphoma; HRS: Hodgkin And Reed-Sternberg; TCL: T-Cell Lymphomas
Introduction | Conclusion | References |